385 related articles for article (PubMed ID: 19798694)
1. GATA3 in development and cancer differentiation: cells GATA have it!
Chou J; Provot S; Werb Z
J Cell Physiol; 2010 Jan; 222(1):42-9. PubMed ID: 19798694
[TBL] [Abstract][Full Text] [Related]
2. GATA-3 and the regulation of the mammary luminal cell fate.
Kouros-Mehr H; Kim JW; Bechis SK; Werb Z
Curr Opin Cell Biol; 2008 Apr; 20(2):164-70. PubMed ID: 18358709
[TBL] [Abstract][Full Text] [Related]
3. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model.
Kouros-Mehr H; Bechis SK; Slorach EM; Littlepage LE; Egeblad M; Ewald AJ; Pai SY; Ho IC; Werb Z
Cancer Cell; 2008 Feb; 13(2):141-52. PubMed ID: 18242514
[TBL] [Abstract][Full Text] [Related]
4. GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis.
Shahi P; Wang CY; Chou J; Hagerling C; Gonzalez Velozo H; Ruderisch A; Yu Y; Lai MD; Werb Z
Oncogene; 2017 Oct; 36(40):5567-5575. PubMed ID: 28581515
[TBL] [Abstract][Full Text] [Related]
5. Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14.
Asselin-Labat ML; Sutherland KD; Vaillant F; Gyorki DE; Wu D; Holroyd S; Breslin K; Ward T; Shi W; Bath ML; Deb S; Fox SB; Smyth GK; Lindeman GJ; Visvader JE
Mol Cell Biol; 2011 Nov; 31(22):4609-22. PubMed ID: 21930782
[TBL] [Abstract][Full Text] [Related]
6. GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells.
Chu IM; Michalowski AM; Hoenerhoff M; Szauter KM; Luger D; Sato M; Flanders K; Oshima A; Csiszar K; Green JE
Oncogene; 2012 Apr; 31(16):2017-27. PubMed ID: 21892208
[TBL] [Abstract][Full Text] [Related]
7. GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse.
McCleskey BC; Penedo TL; Zhang K; Hameed O; Siegal GP; Wei S
Am J Clin Pathol; 2015 Nov; 144(5):756-63. PubMed ID: 26486740
[TBL] [Abstract][Full Text] [Related]
8. GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis.
Dydensborg AB; Rose AA; Wilson BJ; Grote D; Paquet M; Giguère V; Siegel PM; Bouchard M
Oncogene; 2009 Jul; 28(29):2634-42. PubMed ID: 19483726
[TBL] [Abstract][Full Text] [Related]
9. GATA-3 as a marker of hormone response in breast cancer.
Fang SH; Chen Y; Weigel RJ
J Surg Res; 2009 Dec; 157(2):290-5. PubMed ID: 19059610
[TBL] [Abstract][Full Text] [Related]
10. Loss of function of GATA3 induces basal-like mammary tumors.
Bai F; Zheng C; Liu X; Chan HL; Liu S; Ma J; Ren S; Zhu WG; Pei XH
Theranostics; 2022; 12(2):720-733. PubMed ID: 34976209
[No Abstract] [Full Text] [Related]
11. MicroRNA-455-3p mediates GATA3 tumor suppression in mammary epithelial cells by inhibiting TGF-β signaling.
Zeng Y; Gao T; Huang W; Yang Y; Qiu R; Hou Y; Yu W; Leng S; Feng D; Liu W; Teng X; Yu H; Wang Y
J Biol Chem; 2019 Oct; 294(43):15808-15825. PubMed ID: 31492753
[TBL] [Abstract][Full Text] [Related]
12. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
13. Loss of function of GATA3 regulates FRA1 and c-FOS to activate EMT and promote mammary tumorigenesis and metastasis.
Liu X; Bai F; Wang Y; Wang C; Chan HL; Zheng C; Fang J; Zhu WG; Pei XH
Cell Death Dis; 2023 Jun; 14(6):370. PubMed ID: 37353480
[TBL] [Abstract][Full Text] [Related]
14. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
Cakir A; Isik Gonul I; Ekinci O; Cetin B; Benekli M; Uluoglu O
Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
[TBL] [Abstract][Full Text] [Related]
15. GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
Bai F; Zhang LH; Liu X; Wang C; Zheng C; Sun J; Li M; Zhu WG; Pei XH
Theranostics; 2021; 11(17):8218-8233. PubMed ID: 34373738
[No Abstract] [Full Text] [Related]
16. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases.
Lionti S; La Rocca L; Nunnari CM; Barresi V
Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951
[TBL] [Abstract][Full Text] [Related]
17. C1orf106, an innate immunity activator, is amplified in breast cancer and is required for basal-like/luminal progenitor fate decision.
Ma J; Liu C; Yang D; Song J; Zhang J; Wang T; Wang M; Xu W; Li X; Ding S; Zhan J; Zhang H
Sci China Life Sci; 2019 Sep; 62(9):1229-1242. PubMed ID: 31376015
[TBL] [Abstract][Full Text] [Related]
18. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression.
Chou J; Lin JH; Brenot A; Kim JW; Provot S; Werb Z
Nat Cell Biol; 2013 Feb; 15(2):201-13. PubMed ID: 23354167
[TBL] [Abstract][Full Text] [Related]
19. Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer.
Cohen H; Ben-Hamo R; Gidoni M; Yitzhaki I; Kozol R; Zilberberg A; Efroni S
Breast Cancer Res; 2014 Nov; 16(6):464. PubMed ID: 25410484
[TBL] [Abstract][Full Text] [Related]
20. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation.
Asselin-Labat ML; Sutherland KD; Barker H; Thomas R; Shackleton M; Forrest NC; Hartley L; Robb L; Grosveld FG; van der Wees J; Lindeman GJ; Visvader JE
Nat Cell Biol; 2007 Feb; 9(2):201-9. PubMed ID: 17187062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
